<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An update of published clinical advances in the treatment of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> was provided </plain></SENT>
<SENT sid="1" pm="."><plain>Searching MEDLINE using the search terms "<z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e>" and "clinical trials" 46 papers were identified that had been published since the International Conference on <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">Cerebral Vasospasm</z:e> in Istanbul, Turkey in 2006 </plain></SENT>
<SENT sid="2" pm="."><plain>Of these 26 were either safety studies or case reports leaving 20 papers for consideration </plain></SENT>
<SENT sid="3" pm="."><plain>The major topics covered were calcium <z:chebi fb="68" ids="48706">antagonists</z:chebi>, <z:chebi fb="3" ids="32599">magnesium sulphate</z:chebi>, <z:chebi fb="0" ids="35664">statins</z:chebi>, and fasudil <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>The studies published did not reach an impact justified recommended routine use, but certainly as options </plain></SENT>
<SENT sid="5" pm="."><plain>Results of the CONSCIOUS trials on <z:chebi fb="0" ids="51451">endothelin receptor antagonists</z:chebi> are awaited </plain></SENT>
</text></document>